Compositions comprising hemp extract and related treatment methods

Engineered hemp compositions with specific cannabinoid and terpene ratios address the lack of data on hemp product safety and efficacy, offering targeted therapeutic benefits for neurological conditions and enhancing safety for human and animal use.

WO2024229340A1PCT designated stage expired Publication Date: 2024-11-07PORTLAND TECHNOLOGY HOLDINGS LLC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027647
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

There is a need for safer and more targeted hemp products with documented safety and efficacy for treating various medical conditions in humans and animals, as current hemp products lack sufficient published data to support their use.

Method used

The development of non-naturally occurring or engineered compositions comprising specific ratios of decarboxylated and raw hemp extracts, including cannabinoids and terpenes, which are formulated to treat neurological diseases and disorders, with specific concentrations of cannabinoids such as cannabidiol, cannabidiolic acid, cannabigerol, and cannabigerolic acid, to provide effective therapeutic benefits.

Benefits of technology

These compositions offer targeted therapeutic effects for neurological diseases and disorders, improving symptoms and providing safer alternatives for human and veterinary use by leveraging the specific ratios and concentrations of cannabinoids and terpenes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

This disclosure relates to non-naturally occurring hemp extracts comprising cannabinoids and related treatment methods.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS COMPRISING HEMP EXTRACT AND RELATED TREATMENTMETHODSCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 464,112, filed May 4, 2023, the entire disclosure of which is hereby incorporated by referenceFIELD

[0002] This disclosure relates to non-naturally occurring or engineered compositions and methods comprising one or more hemp extracts for the treatment of diseases, disorders, syndromes, and / or conditions in subjects in need.BACKGROUND

[0003] Industrial hemp products with 0.3% or less of tetrahydrocannabinol (THC) are legal according to the Industrial Hemp Act. These products alone or when combined with other cannabinoids are reported to have health benefits including analgesic, anti-anxiety , antiinflammatory, anti-anxiolytic, and anti-epileptic. Additionally, hemp products alone or when combined with other cannabinoids have been shown to be effective in treating a variety of neurological diseases and disorders. There are numerous companies selling hemp products including CBD oil claiming that they are safe and effective for various medical conditions in humans and animals. In the absence of an optimal treatment using traditional pharmacological agents for patients in need, other potentially efficacious pharmacological agents such as cannabinoids are often sought. However, there is very little published data to support safety and efficacy claims for the use of these products in human and veterinary patients.

[0004] Thus, there is a need for safer and more targeted hemp products.DETAILED DESCRIPTION

[0005] It will be appreciated that for clarity, the following disclosure will describe various aspects of embodiments. It should be noted that the specific embodiments are not intended as an exhaustive description or as a limitation to the broader aspects discussed herein. One aspect described in conjunction with a particular embodiment is not necessarily limited tothat embodiment and can be practiced with any other embodiment(s). Reference throughout this specification to "one embodiment", "an embodiment," "an example embodiment," means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment," "in an embodiment," or "an example embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention. For example, in the appended claims, any of the claimed embodiments can be used in any combination.Definitions

[0006] Listed below are definitions of various terms used herein. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

[0007] Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary' skill in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and peptide chemistry are those well- known and commonly employed in the art.

[0008] As used herein, the articles “a” and “an” refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0009] As used herein, when “about” is used to refer to a measurable value such as an amount, a temporal duration, and the like, the term “about” is meant to encompass variations of ±5% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0010] As used in the specification and in the claims, the term “comprising” may include the embodiments “consisting of’ and “consisting essentially of.” The terms “comprise(s),” “include(s),” “having,” “has,” “may,” “contam(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that require the presence ofthe named ingredients / steps and permit the presence of other ingredients / steps. However, such description should be construed as also describing compositions or processes as “consisting of’ and “consisting essentially of’ the enumerated compounds, which allows the presence of only the named compounds, along with any pharmaceutically acceptable carriers, and excludes other compounds.

[0011] All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of “from 50 mg to 500 mg” is inclusive of the endpoints, 50 mg and 500 mg, and all the intermediate values). The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value; they are sufficiently imprecise to include values approximating these ranges and / or values.

[0012] As used herein, the term “treatment” or “treating,” is defined as the application or administration of a therapeutic agent, i.e., a compound provided herein (alone or in combination with another pharmaceutical agent), to a patient or subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient (e.g., for diagnosis or ex vivo applications), with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the symptoms of a disease, disorder, syndrome, or condition. Such treatments can be specifically tailored or modified, based on knowledge obtained from the field of pharmacology.

[0013] In certain embodiments, the compositions described herein treat and / or reduce the severity of a disease, disorder, syndrome, or condition in a subject. For example, the compositions described herein treat and / or improve one or more symptoms of neurological diseases or disorders (e.g., autism, epilepsy, neurodegenerative diseases and disorders, brain and head injury, etc.).

[0014] As used herein, the term “prevent” or “prevention” means no disorder or disease development if none had occurred, or no further disorder or disease development if there had already been development of the disorder or disease. Also considered is the ability7of one to prevent some or all of the symptoms associated with a disorder, disease, and / or condition.

[0015] As used herein, the term “use” includes any one or more of the following embodiments of the invention, respectively: the use in the treatment of a disease, disorder, syndrome, and / or condition for the manufacture of pharmaceutical compositions for use in the treatment of this disease, disorder, syndrome, and / or condition, e.g., in the manufacture and / or preparation of a medicament; methods of use of compounds of the invention in the treatment of this disease, disorder, syndrome, and / or condition; pharmaceutical preparations having compounds of the invention for the treatment of this disease, disorder, syndrome,and / or condition; and compounds of the invention for use in the treatment of this disease, disorder, syndrome, and / or condition; as appropriate and expedient, if not stated otherwise.

[0016] As used herein, the term “patient,” “individual,” or “subject” is intended to include organisms, which are capable of suffering from or afflicted with a disease, disorder, syndrome, and / or condition. Examples of subjects include animals. Examples of subjects include mammals. Examples of subjects include dogs, cats, horses, cows, pigs, sheep, goats, mice, rabbits, rats, birds, fishes, non-human primates, amphibians, reptiles, and transgenic non-human animals. In some embodiments, the subject is a human. In some embodiments, the human subject is an adult (e.g., 18 years of age or older). In some embodiments, the human subject is less than 18 years of age.

[0017] When used with respect to methods of treatment / prevention and the use of the compounds and pharmaceutical compositions thereof described herein, a subject “in need thereof’ may be a subject who has been diagnosed with or previously treated for the condition to be treated. With respect to prevention, the individual in need thereof may also be a subject who is at risk for a condition (e.g., a family history of the disease, disorder, syndrome, and / or condition, life-style factors indicative of risk for the disease, disorder, syndrome, and / or condition, etc.). Typically, when a step of administering a compound of the invention is disclosed herein, the invention further contemplates a step of identifying a subject in need of the particular treatment to be administered or having the particular condition to be treated.

[0018] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material can be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0019] As used herein, the term “pharmaceutically acceptable salt” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with an amount (e.g., a stoichiometric amount) of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.

[0020] As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.

[0021] As used herein, the term “pharmaceutically acceptable carrier” or “carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid (e.g., a solid filler), stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient or subject such that it can perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient or subject. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose, sucrose, and the like; starches, such as com starch potato starch, and the like; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, cellulose acetate, and the like; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter, coconut butter, suppository waxes, and the like; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil, soybean oil, hemp seed oil, linseed oil, fish oil, salmon oil, coconut oil, catnip oil, medium chain triglyceride (MCT) oil, lecithin, grapeseed oil, and the like; polymers such as NF -97 IP polymer; glycols, such as propylene glycol and the like; polyols, such as glycerin, sorbitol, mannitol, polyethylene glycol, and the like; esters, such as ethyl oleate, ethyl laurate, and the like; agar; buffering agents, such as magnesium hydroxide, aluminum hydroxide, and the like; surface active agents; alginic acid; water, such as tap water, purified water, distilledwater, milli-q water, pyrogen-free water, and the like; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial agents, antifungal agents, antioxidant agents, absorption delaying agents, preservative agents, stabilizing agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient or subject. One or more supplementary active and / or inactive compounds can also be incorporated into the compositions. The ■’pharmaceutically acceptable carrier” or “carrier” can further include one or more pharmaceutically acceptable salts of the one or more compounds useful within the invention. Other additional ingredients that can be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0022] The term “stabilizer,” as used herein, refers to polymers capable of chemically inhibiting or preventing degradation. Stabilizers are added to formulations of compounds to improve chemical and physical stability of the compound.

[0023] As used herein, the term “adjuvant” may include, for example, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents.Prevention of the action of microorganisms is generally provided by various antibacterial and antifungal agents, such as, parabens, chlorobutanol, phenol, sorbic acid, and the like. Isotonic agents, such as sugars, sodium chloride, and the like, may also be included. Prolonged absorption of an injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. The auxiliary agents also can include wetting agents, emulsifying agents, pH buffering agents, and antioxidants, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, and the like.

[0024] As used herein, the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction or alleviation of the signs, symptoms, and / or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

[0025] As used herein, the term “weight percent” is meant to refer to the quantity by weightof a compound and / or component in a composition as the quantity by weight of a constituent component of the composition as a percentage of the weight of the total composition. The weight percent can also be calculated by multiplying the mass fraction by 100. The “mass fraction” is the ratio of one substance of a mass ml to the mass of the total composition mT such that weight percent = (ml / mT) * 100. Wherever “%” is used herein, it is assumed to be weight percent unless labeled otherwise.

[0026] “Aqueous buffer” refers to a water solution which resists change in hydronium ion and the hydroxide ion concentration (and consequent pH) upon addition of small amounts of acid or base, or upon dilution. Buffer solutions consist of a weak acid and its conjugate base (more common) and / or a weak base and its conjugate acid (less common). The buffer can be prepared by methods well known in the art with the appropriate buffering agents to give the desired pH value. Examples of the suitable buffering agents include lactic acid, acetic acid, citric acid, malic acid, maleic acid, pyruvic acid, succinic acid, tris- hydroxymethylaminomethane, sodium bicarbonate, phosphoric acid, sodium phosphate, and other biologically acceptable buffering agents. Aqueous buffers are readily available commercially and they can be used in preparation of the compositions of this invention without further treatment.

[0027] As used herein, the term “hemp extract” refers to a composition of cannabinoids and terpenes that are isolated from a hemp plant. The terms “hemp extract,” “CBD oil,” and “hemp oil” have the same meaning and are used interchangeably herein. The hemp extract can be obtained by any method known in the art. For example, the hemp extract can be obtained by supercritical (or subcritical) CO2 extraction, which uses carbon dioxide under high pressure and low temperatures to isolate, preserve and maintain the purity of hemp extract. In an embodiment, the hemp extract is obtained from a supercritical CO2 extraction. For example, supercritical CO2 extraction may be performed as described in U.S. Pat. No. 8,895,078, which is incorporated herein by reference in its entirety. Alternatively, a solvent such as petroleum ether, ethanol, methanol, butane, propane, acetone, dry ice, and / or olive oil can be used, at room temperature (ambient temperature) with stirring, by passive extraction, heated to a temperature above room temperature, or under reflux, as known in the art to provide the hemp extract. In another embodiment, hemp extract from a butanol extraction is employed as starting material for methods disclosed herein.

[0028] In some embodiments a hemp extract is used without undergoing decarboxylation. In some embodiments a hemp extract is used after being decarboxylated. In some embodiments hemp extracts are combined to produce a new hemp extract with a desired composition. Insome embodiments, extracts undergo further purification procedures to increase the concentration of cannabinoids of interest before combination.

[0029] Cannabinoids are compounds isolated from hemp plants. Classes of cannabinoids include for example, without limitation, cannabichromenes, cannabicyclols, cannabidiols, cannabielsoins, cannabigerols, cannabinols, cannabinodiols, cannabitnols, delta-8- tetrahydrocannabinols, and delta-9-tetrahydrocannabinols. Cannabinoid compounds include for example, without limitation, cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV), cannabichromevarinic acid (CBCVA), cannabicyclol (CBL), cannabicyclolic acid (CBLA), cannabicyclovarin (CBLV), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiolic acid (CBD A), cannabidiorcol (CBD-C1), cannabidivarin (CBDV), cannabidivarinic acid (CBDVA), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabielsoin acid A (CBEA-A), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerolic acid (CBGA),cannabigerolic acid monomethylether (CBGAM), cannabigerovarin (CBGV), cannabigerovarinic acid (CBGVA), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabinol (CBN), cannabinol methylether (CBNM), cannabinol-C2 (CBN-C2), cannabinol-C4 (CBN-C4), cannabinolic acid (CBNA), cannabiorcool (CBN-C1), cannabivarin (CBV), 10-Ethoxy-9-hydroxy-delta- 6a-tetrahydrocannabinol, 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol, cannabitriol (CBT), cannabitriolvarin (CBTV), delta-8-tetrahydrocannabinol (A8-THC), delta-8- tetrahydrocannabinolic acid (A8-THCA), delta-9-tetrahydrocannabinol (THC), delta-9- tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta- 9-tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinolic acid-C4 (THCA- C4), delta-9-tetrahydrocannabiorcol (THC -Cl), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta-9-tetrahydrocannabivarin (THCV), delta-9-tetrahydrocannabivarinic acid (THCVA), 10-Oxo-delta-6a-tetrahydrocannabinol (OTHC), cannabichromanon (CBCF), cannabifuran (CBF), cannabiglendol, cannabiripsol (CBR), cannabicitran (CBT), ehydrocannabifuran (DCBF), delta-9-cis-tetrahydrocannabinol (cis-THC), and tryhydroxy- delta-9-tetrahydrocannabinol (triOH-THC).

[0030] Suitable methods for measuring the cannabinoid and terpene content in the hemp extract are known in the art. In an embodiment, cannabinoid content is determined using liquid chromatography with mass spectrometry detection (LC-MS). In another embodiment, terpene content is determined using gas chromatography with flame ionization detection (GC-FID) analysis of headspace.

[0031] As used herein, the term “flavoring agent” refers to an ingredient that is added to acomposition to impart a particular flavor, smell, or other organoleptic property. The flavoring agent can be natural or artificial.

[0032] As used herein, the term “oil” refers to a nonpolar viscous liquid that is both hydrophobic and lipophilic. Oils may be isolated from animal, vegetable, or petrochemical products.

[0033] The “maximal serum concentration level” of a substance, as used herein, refers to the maximal level of the substance found in a plasma sample following a single administration.

[0034] As used herein, the term “cold extrusion” refers to a process for producing edible food products comprising several unit operations including adding, mixing, kneading, pressing, shearing, shaping, and forming, all of which are conducted at or near ambient temperature.

[0035] As used herein, the term “psychotropic effect” refers to a modification of brain function that results in an alteration of perception, mood, consciousness, and / or behavior.

[0036] As used herein, the term “paste” refers to a product or a portion thereof that has rheological and chemical properties which are consistent with containing and delivering pharmaceutical compositions (e.g., a composition comprising a hemp extract) via the mouth. For example, a paste can be applied to the luminal surfaces of the oral cavity (e.g., gums, inner cheeks). Generally speaking, a paste will be sufficiently spreadable that it can be appropriately applied. Additionally, the paste may be flavored and / or exhibit a mouthfeel or texture that promotes consumption by the animal. Thus, in some embodiments, the paste is palatable for the animal to which the paste is applied. In some embodiments, the paste is hydrophobic. In some embodiments, pastes of the present disclosure can be applied to pets by veterinary professionals or by pets’ owners.

[0037] As used herein, the term “gel” refers to a product or a portion thereof that is an aggregate of fine particles dispersed in a liquid medium, wherein the medium has become viscous enough to behave in some ways like a solid. Additionally, the gel may be flavored and / or exhibit a mouthfeel or texture that promotes consumption by an animal. Thus, in some embodiments, the gel is palatable for the animal to which the gel is applied. In some embodiments, the gel is hydrophilic. In some embodiments, gels of the present disclosure can be applied to pets by veterinary professionals or by pets’ owners.Overview

[0038] The embodiments disclosed herein provide non-naturally occurring or engineered compositions and methods comprising one or more hemp extracts for the treatment of diseases, disorders, syndromes, and / or conditions in subjects in need. The diseases,disorders, syndromes, and / or conditions comprise for example, without limitation, neurological diseases and disorders (e.g., autism, epilepsy, neurodegenerative diseases and disorders, brain and head injury, etc.).Hemp Extracts - Cannabinoid Compositions

[0039] In one aspect, provided herein is a hemp extract comprising a raw hemp extract and a decarboxylated hemp extract. As used herein, a “raw hemp extract” is one that is not subject to heating or other conditions that leads to substantial conversion of acidic forms of cannabinoids to their non-acidic forms. As used herein, a “decarboxylated hemp extract” is one where most of the cannabinoids in the extract have been converted from their acidic forms to their non-acidic forms. For example, acidic forms include CBDA, CBGA, and CBDVA, and their corresponding non-acidic forms are CBD, CBG, and CBDV.

[0040] In some embodiments, the hemp extract comprises a specific ratio of decarboxylated hemp extract to raw hemp extract. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is less than about 1: 1, e.g., less than about 1:2, less than about 1:3, less than about 1 :5, less than about 1: 10, less than about 1 :20, less than about 1:25, less than about 1:30, less than about 1:40, less than about 1:50, less than about 1:75, less than about 1 :100, less than about 1:200, less than about 1:300, less than about 1 :400, less than about 1 :500, less than about 1:600, less than about 1:700, less than about 1 :800, less than about 1 :900, or less than about 1 :1000. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is less than about 1: 100. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is less than about 1 : 1000. In some embodiments, the hemp extract comprises only a raw hemp extract.

[0041] In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is about 0.1 :1 to about 1:0.1. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is about 0.1: 1, about 0.2:1, about 0.3: 1, about 0.4:1, about 0.5: 1, about 0.6: 1, about 0.7: 1, about 0.8: 1, about 0.9:1, about 1: 1, about 1:0.9, about 1:0.8, about 1:0.7, about 1 :0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2, or about 1 :0.1. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is about 0.6: 1 to about 1 :0.6. In some embodiments, the ratio of decarboxylated hemp extract to raw hemp extract is about 1 :1.

[0042] In some embodiments, a hemp extract provided herein comprising a raw hemp extract and a decarboxylated hemp extract further comprises at least one of cannabigerolic acid, A9- tetrahydrocannabinolic acid, and cannabichromene. In some embodiments, a hemp extractprovided herein comprising a raw hemp extract and a decarboxylated hemp extract further comprises cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene.

[0043] In another aspect, provided herein is a hemp extract comprising cannabidiolic acid (termed herein a “CBDA extract”). In some embodiments, the CBDA extract comprises some trace amount of CBD. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1 :25, less than about 1 :30, less than about 1 :40, less than about 1:50, less than about 1 :75, less than about 1 : 100, less than about 1:200, less than about 1 :300, less than about 1:400, less than about 1:500, less than about 1:600, less than about 1:700, less than about 1:800, less than about 1:900, or less than about 1: 1000. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1: 100. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1: 1000.

[0044] In some embodiments, a CBDA extract provided herein comprises 20 mg / mL to 70 mg / mL cannabidiolic acid. In some embodiments, the CBDA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 12 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 11 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 10 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 9 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 8 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0045] In some embodiments, the CBDA extract comprises cannabidiolic acid at a concentration of 20 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 40 mg / mL to 50 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 25 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration ofabout 30 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 35 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 4% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 4% by weight to 6% by weight of cannabidiolic acid.

[0046] In some embodiments, the CBDA extract comprises 20 mg / mL to 40 mg / mL of cannabidiolic acid. In some embodiments, the CBDA extract comprises 25 mg / mL to 35 mg / mL of cannabidiolic acid. In some embodiments, the CBDA extract comprises 30 mg / mL to 40 mg / mL of cannabidiolic acid. In some embodiments, the CBDA extract comprises 30 mg / mL to 60 mg / mL of cannabidiolic acid. In some embodiments the CBDA extract comprises 40 mg / mL to 50 mg / mL of cannabidiolic acid.

[0047] In some embodiments, the CBDA extract provided herein further comprises at least one of cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene. In some embodiments, the CBDA extract provided herein further comprises cannabigerolic acid, A9- tetrahydrocannabinolic acid, and cannabichromene.

[0048] In another aspect, provided herein is a hemp extract comprising cannabidiol and cannabidiolic acid (termed herein a “CBD-CBDA extract”). In some embodiments, the CBD- CBDA extract comprises a specific ratio of cannabidiol to cannabidiolic acid. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1 :1, e.g., less than about 1:2, less than about 1:3, less than about 1:5, less than about 1: 10, less than about 1:20, less than about 1 :25, less than about 1 :30, less than about 1:40, less than about 1:50, less than about 1 :75, less than about 1 : 100, less than about 1:200, less than about 1 :300, less than about 1:400, less than about 1:500, less than about 1:600, less than about 1:700, less than about 1 :800, less than about 1:900, or less than about 1: 1000. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1: 100. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1: 1000. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 1 : 100, about 1 :50, about 1 : 10, or about 1: 1.

[0049] In some embodiments, the ratio of cannabidiol to cannabidiolic acid in a CBD-CBDA extract provided herein is about 0.1: 1 to about 1:0.1. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 0.1: 1, about 0.2: 1, about 0.3: 1, about 0.4: 1, about 0.5: 1, about 0.6: 1, about 0.7: 1, about 0.8:1, about 0.9: 1, about 1:1, about 1:0.9, about 1:0.8,about 1 :0.7, about 1:0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2, or about 1:0.1. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1:0.6. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 1: 1.

[0050] In some embodiments, a CBD-CBDA extract provided herein comprises 20 mg / mL to 70 mg / mL of cannabidiol and 20 mg / mL to 70 mg / mL cannabidiolic acid. In some embodiments, the CBD-CBDA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 12 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 11 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 10 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 9 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 8 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0051] In some embodiments, the CBD-CBDA extract comprises cannabidiol at a concentration of 20 mg / mL to 40 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 40 mg / mL to 50 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 25 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 30 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 35 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabidiol. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiol. In some embodiments, the hemp extract comprises 3% to 4% by weight of cannabidiol. In some embodiments, the hemp extract comprises 3% by weight to 6% by weight of cannabidiol. In some embodiments, the hemp extract comprises 4% by weight to 6% by weight cannabidiol.

[0052] In some embodiments, the CBD-CBDA extract comprises cannabidiolic acid at a concentration of 20 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 40 mg / mL to 50 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 25 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 30 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 35 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 4% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 4% by weight to 6% by weight of cannabidiolic acid.

[0053] In some embodiments, the CBD-CBDA extract comprises 20 mg / mL to 40 mg / mL of cannabidiol and 20 mg / mL to 40 mg / mL of cannabidiolic acid. In some embodiments, the CBD-CBDA extract comprises 25 mg / mL to 35 mg / mL of cannabidiol and 25 mg / mL to 35 mg / mL of cannabidiolic acid. In some embodiments, the CBD-CBDA extract comprises 30 mg / mL to 40 mg / mL of cannabidiol and 30 mg / mL to 40 mg / mL of cannabidiolic acid. In some embodiments, the CBD-CBDA extract comprises 30 mg / mL to 60 mg / mL of cannabidiol and 30 mg / mL to 60 mg / mL of cannabidiolic acid. In some embodiments the CBD-CBDA extract comprises 40 mg / mL to 50 mg / mL of cannabidiol and 40 mg / mL to 50 mg / mL of cannabidiolic acid.

[0054] In some embodiments, a CBD extract is combined with a CBDA extract. In some embodiments, the final extract comprises 3% to 9% by weight of each extract, respectively. In some embodiments, the final extract comprises about 6.3% by weight of each extract, respectively.

[0055] In some embodiments, a CBD-CBDA extract provided herein further comprises at least one of cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabi chromene. In some embodiments, a CBD-CBDA extract provided herein further comprises cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene.

[0056] In another aspect, provided herein is a hemp extract comprising cannabigerol and cannabigerolic acid (termed herein a ' CBG-CBGA extract”). In some embodiments, the CBG-CBGA extract comprises a specific ratio of cannabigerol to cannabigerolic acid. In some embodiments, the ratio of cannabigerol to cannabigerolic acid is less than about 1 : 1, e.g., less than about 1:2, less than about 1:3, less than about 1:5, less than about 1 :10, less than about 1:20, less than about 1:25, less than about 1:30, less than about 1:40, less than about 1 :50, less than about 1 :75, less than about 1: 100, less than about 1:200, less than about 1:300, less than about 1:400, less than about 1:500. In some embodiments, the ratio of cannabigerol to cannabigerolic acid is about 1: 100, about 1:50, about 1 : 10, or about 1 : 1.

[0057] In some embodiments, the ratio of cannabigerol to cannabigerolic acid in a CBG- CBGA extract provided herein is about 0.1: 1 to about 1:0.1. In some embodiments, the ratio of cannabigerol to cannabigerolic acid is about 0.1: 1, about 0.2: 1, about 0.3:1, about 0.4: 1, about 0.5:1, about 0.6: 1, about 0.7: 1, about 0.8: 1, about 0.9: 1, about 1: 1, about 1:0.9, about 1:0.8, about 1:0.7, about 1:0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2, or about 1:0.1. In some embodiments, the ratio of cannabigerol to cannabigerolic acid is about 0.6: 1 to about 1 :0.6. In some embodiments, the ratio of cannabigerol to cannabigerolic acid is about 1: 1.

[0058] In some embodiments, a CBG-CBGA extract provided herein comprises 20 mg / mL to 70 mg / mL of cannabigerol and 25 mg / mL to 70 mg / mL cannabigerolic acid. In some embodiments, the CBG-CBGA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0059] In some embodiments, the CBG-CBGA extract comprises cannabigerol at a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 28 mg / mL to 32 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 40 mg / mL to 55 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 28 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 29 mg / mL. In someembodiments, the cannabigerol is present at a concentration of about 30 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 31 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 32 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabigerol. In some embodiments, the hemp extract comprises 1% by weight to 5% by weight of cannabigerol. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabigerol. In some embodiments, the hemp extract comprises 3% by weight to 7% by weight of cannabigerol. In some embodiments, the hemp extract comprises 3% by weight to 6% by weight of cannabigerol.

[0060] In some embodiments, the CBG-CBGA extract comprises cannabigerolic acid at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 32 mg / mL to 37 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 40 mg / mL to 55 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 32 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 33 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 34 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 35 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 36 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 37 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 1% by weight to 5% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 3% by weight to 7% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 3% by weight to 6% by weight of cannabigerolic acid.

[0061] In some embodiments, the CBG-CBGA extract comprises 25 mg / mL to 35 mg / mL of cannabigerol and 30 mg / mL to 40 mg / mL of cannabigerolic acid. In some embodiments, the CBG-CBGA extract comprises 28 mg / mL to 32 mg / mL of cannabigerol and 32 mg / mL to 37 mg / mL of cannabigerolic acid. In some embodiments, the CBG-CBGA extract comprises 30 mg / mL to 40 mg / mL of cannabigerol and 30 mg / mL to 40 mg / mL of cannabigerolic acid. In some embodiments, the CBG-CBGA extract comprises 30 mg / mL to 60 mg / mL ofcannabigerol and 30 mg / mL to 60 mg / mL of cannabigerolic acid. In some embodiments, the CBG-CBGA extract comprises 40 mg / mL to 55 mg / mL of cannabigerol and 40 mg / mL to 55 mg / mL of cannabigerolic acid.

[0062] In some embodiments, a CBG extract is combined with a CBGA extract. In some embodiments, the final extract comprises 3% to 9% by weight of the CBG extract and 2% to 8% by weight of the CBGA. In some embodiments, the final extract comprises about 6.1% by weight of the CBGA extract and about 4.9% by weight of the CBG extract.

[0063] In another aspect, provided herein is a hemp extract comprising cannabidiolic acid, cannabigerolic acid, and cannabigerol (termed herein a “CBDA-CBGA-CBG extract”). In some embodiments, the CBDA-CBGA-CBG extract comprises a specific ratio of cannabidiolic acid, cannabigerolic acid, and cannabigerol. In some embodiments, the ratio of cannabidiolic acid, cannabigerolic acid, and cannabigerol is 1.6-2.4:0.8-1.2:0.8-1.2. In some embodiments, the ratio of cannabidiolic acid, cannabigerolic acid, and cannabigerol is 2: 1: 1.

[0064] In some embodiments, the CBDA-CBGA-CBG extract comprises a specific ratio of cannabidiolic acid to cannabigerolic acid. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is less than about 1: 1, e.g., less than about 1:2, less than about 1:3, less than about 1 :5, less than about 1:10, less than about 1:20, less than about 1:25, less than about 1 :30, less than about 1 :40, less than about 1:50, less than about 1:75, less than about 1: 100, less than about 1:200, less than about 1:300, less than about 1:400, less than about 1:500. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is about 1: 100, about 1:50, about 1: 10, or about 1:1. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is about 0.1: 1 to about 1 :0.1. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is about 0.1: 1, about 0.2: 1, about 0.3: 1, about 0.4: 1, about 0.5:1, about 0.6: 1, about 0.7: 1, about 0.8: 1, about 0.9: 1, about 1: 1, about 1:0.9, about 1:0.8, about 1:0.7, about 1:0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2, or about 1:0.1. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is about 0.6: 1 to about 1 :0.6. In some embodiments, the ratio of cannabidiolic acid to cannabigerolic acid is about 1: 1.

[0065] In some embodiments, a CBDA-CBGA-CBG extract provided herein comprises 20 mg / mL to 70 mg / mL of cannabidiolic acid, 20 mg / mL to 70 mg / mL cannabigerolic acid, and 1 mg / mL to 10 mg / mL of cannabigerol. In some embodiments, the CBDA-CBGA-CBG extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than6 mg / mL, individually. In someembodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0066] In some embodiments, the CBDA-CBGA-CBG extract comprises cannabigerol is present at 2 mg / mL to 8 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 2 mg / mL to 7 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 2 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 3 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 4 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 5 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 6 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 7 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 8 mg / mL. In some embodiments, the hemp extract comprises less than 1% by weight of cannabigerol. In some embodiments, the hemp extract comprises less than 0.5% by weight of cannabigerol.

[0067] In some embodiments, the CBDA-CBGA-CBG extract comprises cannabigerolic acid at a concentration of 25 mg / mL to 40 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 30 mg / mL to 34 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 40 mg / mL to 55 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 30 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 31 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 32 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 33 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 34 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 35 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabigerolicacid. In some embodiments, the hemp extract comprises 3% by weight to 6% by weight of cannabigerolic acid.

[0068] In some embodiments, the CBDA-CBGA-CBG extract comprises cannabidiolic acid at a concentration of 25 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 34 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 40 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 60 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 40 mg / mL to 55 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 30 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 31 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 32 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 33 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 34 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 35 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 3% by weight to 6% by weight of cannabidiolic acid.

[0069] In some embodiments, the CBDA-CBGA-CBG extract comprises 25 mg / mL to 40 mg / mL of cannabidiolic acid; 25 mg / mL to 40 mg / mL cannabigerolic acid; and 2 mg / mL to 8 mg / mL of cannabigerol. In some embodiments, the CBDA-CBGA-CBG extract comprises 30 mg / mL to 34 mg / mL of cannabidiolic acid; 30 mg / mL to 34 mg / mL of cannabigerolic acid; and 2 mg / mL to 7 mg / mL of cannabigerol. In some embodiments, the CBDA-CBGA-CBG extract comprises 30 mg / mL to 40 mg / mL of cannabidiolic acid; 30 mg / mL to 40 mg / mL cannabigerolic acid; and 1 mg / mL to 10 mg / mL of cannabigerol. In some embodiments, the CBDA-CBGA-CBG extract comprises 30 mg / mL to 60 mg / mL of cannabidiolic acid; 30 mg / mL to 60 mg / mL of cannabigerolic acid; and 2 mg / mL to 8 mg / mL of cannabigerol. In some embodiments, the CBDA-CBGA-CBG extract comprises 40 mg / mL to 55 mg / mL of cannabidiolic acid; 40 mg / mL to 55 mg / mL of cannabigerolic acid; and 2 mg / mL to 8 mg / mL of cannabigerol.

[0070] In some embodiments, a CBDA extract is combined with a CBGA extract. In some embodiments, the final extract comprises 3% to 9% by weight of the CBDA extract and 3%to 8% by weight of the CBGA. In some embodiments, the final extract comprises about 5.7% by weight of the CBGA extract and about 6.4% by weight of the CBDA extract.

[0071] In some embodiments, a CBDA-CBGA-CBG extract provided herein further comprises at least one of A9-tetrahydrocannabinolic acid and cannabichromene. In some embodiments, a CBDA-CBGA-CBG extract provided herein further comprises A9- tetrahydrocannabinolic acid and cannabichromene.

[0072] In another aspect, provided herein is a hemp extract comprising cannabidiol, cannabidiolic acid, cannabidivarin, cannabidivarinic acid, and cannabigerolic acid (termed herein a “CBD-CBDA-CBDV-CBDVA-CBGA extract”). In some embodiments, a CBD- CBDA-CBDV-CBDVA-CBGA extract provided herein comprises 10 mg / mL to 50 mg / mL of cannabidiol, 5 mg / mL to 35 mg / mL cannabidiolic acid, 5 mg / mL to 35 mg / mL of cannabidivarin, 3 mg / mL to 25 mg / mL cannabidivarinic acid, and 3 mg / mL to 20 mg / mL of cannabigerolic acid. In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0073] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises cannabidivarin at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the extract comprises cannabidivarin at a concentration of 13 mg / mL to 17 mg / mL. In some embodiments, the extract comprises cannabidivarin at a concentration of 15 mg / mL to 30 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 13 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 14 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 15 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 16 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 18 mg / mL. In some embodiments, the hemp extract comprises 0.5% by weight to 5% by weight of cannabidivarin. In some embodiments, the hemp extract comprises 0.5% by weight to 2%by weight of cannabidivarin. In some embodiments, the hemp extract comprises 1% by weight to 3% by weight of cannabidivarin.

[0074] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises cannabidivarinic acid at a concentration of 5 mg / mL to 15 mg / mL. In some embodiments, the extract comprises cannabidivarinic acid at a concentration of 8 mg / mL to 13 mg / mL. In some embodiments, the extract comprises cannabidivarinic acid at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 8 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 9 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 10 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 11 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 12 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 13 mg / mL. In some embodiments, the hemp extract comprises 0.5% by weight to 4% by weight of cannabidivarinic acid. In some embodiments, the hemp extract comprises 0.5% by weight to 2% by weight of cannabidivarinic acid. In some embodiments, the hemp extract comprises 1% by weight to 3% by weight of cannabidivarinic acid.

[0075] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises cannabidiol at a concentration of 15 mg / mL to 25 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 18 mg / mL to 22 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 20 mg / mL to 40 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 18 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 19 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 20 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 21 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 22 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 4% by weight of cannabidiol. In some embodiments, the hemp extract comprises 1% by weight to 3% by weight of cannabidiol. In some embodiments, the hemp extract comprises 2% by weight to 4% by weight of cannabidiol.

[0076] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises cannabigerolic acid at a concentration of 5 mg / mL to 10 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 8 mg / mL to 20 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 5 mg / mL. Insome embodiments, the cannabigerolic acid is present at a concentration of about 6 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 7 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 8 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 9 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 10 mg / mL. In some embodiments, the hemp extract comprises 0.5% by weight to 4% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 0.5% by weight to 3% by weight of cannabigerolic acid. In some embodiments, the hemp extract comprises 1% by weight to 4% by weight of cannabigerolic acid.

[0077] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises cannabidiolic acid at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 13 mg / mL to 17 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 10 mg / mL to 30 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 13 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 14 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 15 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 16 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 17 mg / mL. In some embodiments, the hemp extract comprises 0.5% by weight to 5% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 0.5% by weight to 3% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 1% by weight to 4% by weight of cannabidiolic acid.

[0078] In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises 15 mg / mL to 25 mg / mL of cannabidiol; 10 mg / mL to 20 mg / mL cannabidiolic acid; 10 mg / mL to 20 mg / mL of cannabidivarin; 5 mg / mL to 15 mg / mL cannabidivarinic acid; and 5 mg / mL to 10 mg / mL of cannabigerolic acid. In some embodiments, the CBD-CBDA-CBDV- CBDVA-CBGA extract comprises 18 mg / mL to 22 mg / mL of cannabidiol; 13 mg / mL to 17 mg / mL cannabidiolic acid; 13 mg / mL to 17 mg / mL of cannabidivarin; 8 mg / mL to 13 mg / mL cannabidivarinic acid; and 5 mg / mL to 10 mg / mL of cannabigerolic acid. In some embodiments, the CBD-CBDA-CBDV-CBDVA-CBGA extract comprises 20 mg / mL to 40 mg / mL of cannabidiol; 10 mg / mL to 30 mg / mL cannabidiolic acid; 15 mg / mL to 30 mg / mL of cannabidivarin; 10 mg / mL to 20 mg / mL cannabidivarinic acid; and 8 mg / mL to 20 mg / mL of cannabigerolic acid.

[0079] In some embodiments, a CBDVA extract is combined with a CBDV extract. In some embodiments, the final extract comprises 3% to 9% by weight of the CBDV extract and 3% to 9% by weight of the CBDVA. In some embodiments, the final extract comprises about 6. 15% by weight of the CBDV extract and about 6. 15% by weight of the CBDVA extract. Other cannabinoids present in the CBDVA and / or CBDV extracts are the source of the remaining cannabinoids.

[0080] In another aspect, provided herein is a hemp extract comprising cannabidiol, cannabidiolic acid, cannabigerol, and cannabigerolic acid (termed herein a “CBD-CBDA- CBG-CBGA extract”). In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises a specific ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, and cannabigerol. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, and cannabigerol is 0.8-1.2:0.8-1.2:0.8-1.2:0.8-l .2. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, and cannabigerol is 1 : 1 : 1 : 1.

[0081] In some embodiments, a CBD-CBDA-CBG-CBGA extract provided herein comprises 5 mg / mL to 30 mg / mL of cannabidiol, 5 mg / mL to 30 mg / mL cannabidiolic acid, 5 mg / mL to 30 mg / mL of cannabigerol, and 5 mg / mL to 30 mg / mL cannabigerolic acid. In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0082] In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises cannabigerol at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the extract comprises cannabigerol at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 17 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 18 mg / mL.

[0083] In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises cannabigerolic acid at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the extract comprises cannabigerolic acid at a concentration of 12 mg / mL to 22 mg / mL. In someembodiments, the cannabigerolic acid is present at a concentration of about 17 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 18 mg / mL.

[0084] In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises cannabidiol at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 18 mg / mL.

[0085] In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises cannabidiolic acid at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 18 mg / mL.

[0086] In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises 10 mg / mL to 25 mg / mL of cannabidiol; 10 mg / mL to 25 mg / mL cannabidiolic acid; 10 mg / mL to 25 mg / mL of cannabigerol; and 10 mg / mL to 25 mg / mL cannabigerolic acid. In some embodiments, the CBD-CBDA-CBG-CBGA extract comprises 12 mg / mL to 22 mg / mL of cannabidiol; 12 mg / mL to 22 mg / mL cannabidiolic acid; 12 mg / mL to 22 mg / mL of cannabigerol; and 12 mg / mL to 22 mg / mL cannabigerolic acid.

[0087] In some embodiments, a CBD-CBDA-CBG-CBGA extract provided herein further comprises at least one of cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene. In some embodiments, a CBD-CBDA-CBG-CBGA extract provided herein further comprises cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene.

[0088] In another aspect, provided herein is a hemp extract comprising cannabidiol, cannabidiolic acid, cannabidivarin, and cannabidivarinic acid (termed herein a “CBD-CBDA- CBDV-CBDVA extract”). In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises a specific ratio of cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin is 2.4-3.6:0.8-1.2:0.8-1.2: 0.8-1.2. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin is 3 : 1 : 1 : 1.

[0089] In some embodiments, a CBD-CBDA-CBDV-CBDVA extract provided herein comprises 5 mg / mL to 30 mg / mL of cannabidiol, 5 mg / mL to 30 mg / mL cannabidiolic acid, 5 mg / mL to 30 mg / mL of cannabidivarin, and 5 mg / mL to 30 mg / mL cannabidivarinic acid.In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0090] In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises cannabi divarin at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the extract comprises cannabidivarin at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidivarin is present at a concentration of about 18 mg / mL.

[0091] In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises cannabidivarinic acid at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the extract comprises cannabidivarinic acid at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidivarinic acid is present at a concentration of about 18 mg / mL.

[0092] In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises cannabidiol at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 18 mg / mL.

[0093] In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises cannabidiolic acid at a concentration of 10 mg / mL to 25 mg / mL. In some embodiments, the cannabi diolic acid is present at a concentration of 12 mg / mL to 22 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 17 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 18 mg / mL.

[0094] In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises 10 mg / mL to 25 mg / mL of cannabidiol; 10 mg / mL to 25 mg / mL cannabidiolic acid; 10 mg / mL to 25 mg / mL of cannabidivarin; and 10 mg / mL to 25 mg / mL cannabidivarinic acid. In some embodiments, the CBD-CBDA-CBDV-CBDVA extract comprises 12 mg / mL to 22 mg / mLof cannabidiol; 12 mg / mL to 22 mg / mL cannabidiolic acid; 12 mg / mL to 22 mg / mL of cannabidivarin; and 12 mg / mL to 22 mg / mL cannabidivarinic acid.

[0095] In some embodiments, a CBD-CBDA-CBDV-CBDVA extract provided herein further comprises at least one of cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene. In some embodiments, a CBD-CBDA-CBDV-CBDVA extract provided herein further comprises cannabigerolic acid, A9-tetrahydrocannabinolic acid, and cannabichromene.

[0096] In another aspect, provide herein is a hemp extract comprising cannabidiol, cannabidiolic acid, and cannabinol (termed herein a “CBD-CBDA-CBN extract”). In some embodiments, the CBD-CBDA-CBN extract comprises a specific ratio of cannabidiol to cannabidiolic acid. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is less than about 1 : 1, e.g., less than about 1:2, less than about 1:3, less than about 1 :5, less than about 1 :10, less than about 1 :20, less than about 1:25, less than about 1:30, less than about 1:40, less than about 1 :50, less than about 1 :75, less than about 1: 100, or less than about 1:200. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 1: 100, about 1 :50, about 1 :10, or about 1 : 1.

[0097] In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 0.1: 1 to about 1 :0.1. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 0.1 : 1, about 0.2: 1, about 0.3: 1, about 0.4:1, about 0.5: 1, about 0.6:1, about 0.7: 1, about 0.8:1, about 0.9:1, about 1: 1, about 1:0.9, about 1:0.8, about 1:0.7, about 1 :0.6, about 1:0.5, about 1:0.4, about 1:0.3, about 1:0.2, or about 1:0.1. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 0.6:1 to about 1 :0.6. In some embodiments, the ratio of cannabidiol to cannabidiolic acid is about 1: 1.

[0098] In some embodiments, a CBD-CBDA-CBN extract provided herein comprises 20 mg / mL to 60 mg / mL of cannabidiol, 20 mg / mL to 60 mg / mL of cannabidiolic acid, and 5 mg / mL to 30 mg / mL of cannabinol. In some embodiments, the CBD-CBDA-CBN extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0099] In some embodiments, the CBD-CBDA-CBN extract comprises cannabidiolic acid at a concentration of 20 mg / mL to 40 mg / mL, In some embodiments, the cannabidiolic acid is present at a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 55 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 30 mg / mL to 45 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 25 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 26 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 27 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 28 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 29 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 30 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of about 40 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 7% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 1% by weight to 4% by weight of cannabidiolic acid. In some embodiments, the hemp extract comprises 2% by weight to 5% by weight of cannabidiolic acid.

[0100] In some embodiments, the CBD-CBDA-CBN extract comprises cannabinol at a concentration of 5 mg / mL to 20 mg / mL. In some embodiments, the cannabinol is present at a concentration of 8 mg / mL to 12 mg / mL. In some embodiments, the cannabinol is present at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 8 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 9 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 10 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 11 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 12 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 13 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 14 mg / mL. In some embodiments, the cannabinol is present at a concentration of about 15 mg / mL. In some embodiments, the hemp extract comprises 0.5% by weight to 4% by weight of cannabinol. In some embodiments, the hemp extract comprises 0.5% by weight to 3% by weight of cannabinol. In some embodiments, the hemp extract comprises 1% by weight to 3% by weight of cannabinol. In some embodiments, the hemp extract comprises 1% by weight to 2% by weight of cannabinol.

[0101] In some embodiments, the CBD-CBDA-CBN extract comprises cannabidiol at a concentration of 20 mg / mL to 40 mg / mL. In some embodiments, the cannabidiol is presentat a concentration of 25 mg / mL to 35 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 30 mg / mL to 55 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 30 mg / mL to 45 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 25 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 26 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 27 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 28 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 29 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 30 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 36 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 37 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 38 mg / mL. In some embodiments, the hemp extract comprises 1% by weight to 6% by weight of cannabidiol. In some embodiments, the hemp extract comprises 1.5% by weight to 4% by weight of cannabidiol. In some embodiments, the hemp extract comprises 2.5% by weight to 5% by weight of cannabidiol.

[0102] In some embodiments, the CBD-CBDA-CBN extract comprises 20 mg / mL to 40 mg / mL of cannabidiol; 20 mg / mL to 40 mg / mL of cannabidiolic acid; and 5 mg / mL to 20 mg / mL of cannabinol. In some embodiments, the CBD-CBDA-CBN extract comprises 25 mg / mL to 35 mg / mL of cannabidiol; 25 mg / mL to 35 mg / mL of cannabidiolic acid; and 8 mg / mL to 12 mg / mL of cannabinol. In some embodiments, the CBD-CBDA-CBN extract comprises 30 mg / mL to 55 mg / mL of cannabidiol; 30 mg / mL to 55 mg / mL of cannabidiolic acid; and 10 mg / mL to 20 mg / mL of cannabinol. In some embodiments, the CBD-CBDA- CBN extract comprises 30 mg / mL to 45 mg / mL of cannabidiol; 30 mg / mL to 45 mg / mL of cannabidiolic acid; and 10 mg / mL to 20 mg / mL of cannabinol.

[0103] In some embodiments, a CBDA extract, CBD extract, and a CBN extract are combined. In some embodiments, the final extract comprises 3% to 8% by weight of the CBDA extract, 3% to 8% by weight of the CBD extract, and 0.5% to 3% by weight of the CBN extract. In some embodiments, the final extract comprises about 5.4% by weight of the CBDA extract, about 5.35% by weight of the CBD extract, and about 1. 11% by weight of the CBN extract.

[0104] In another aspect, provided herein is a hemp extract comprising cannabidiol, cannabigerol, and cannabigerohc acid (termed herein a “CBD-CBG-CBGA extract”). In some embodiments, a CBD-CBG-CBGA extract provided herein comprises 20 mg / mL to 50 mg / mL of cannabidiol, 5 mg / mL to 25 mg / mL of cannabigerol, and 5 mg / mL to 25 mg / mL ofcannabigerolic acid. In some embodiments, the CBD-CBG-CBGA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0105] In some embodiments, the CBD-CBG-CBGA extract comprises cannabidiol at a concentration of 25 mg / mL to 45 mg / mL. In some embodiments, the cannabidiol is present at a concentration of 30 mg / mL to 45 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 41 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 40 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 39 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 36 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 37 mg / mL. In some embodiments, the cannabidiol is present at a concentration of about 38 mg / mL.

[0106] In some embodiments, the CBD-CBG-CBGA extract comprises cannabigerol at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabigerol is present at a concentration of 13 mg / mL to 20 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 14 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 15 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 16 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 17 mg / mL. In some embodiments, the cannabigerol is present at a concentration of about 18 mg / mL.

[0107] In some embodiments, the CBD-CBG-CBGA extract comprises cannabigerolic acid at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 10 mg / mL to 20 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 13 mg / mL to 20 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 14 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 15 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 16 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about17 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of about 18 mg / mL.

[0108] In some embodiments, the CBD-CBG-CBGA extract comprises 25 mg / mL to 45 mg / mL of cannabidiol; 10 mg / mL to 20 mg / mL of cannabigerol; and 10 mg / mL to 20 mg / mL of cannabigerolic acid. In some embodiments, the CBD-CBG-CBGA extract comprises 30 mg / mL to 45 mg / mL of cannabidiol; 13 mg / mL to 20 mg / mL of cannabigerol; and 13 mg / mL to 20 mg / mL of cannabigerolic acid.

[0109] In some embodiments, a CBD extract, CBG extract, and a CBGA extract are combined. In some embodiments, the final extract comprises 2% to 8% by weight of the CBD extract, 0.5% to 3% by weight of the CBG extract, and 0.5% to 3% by weight of the CBGA extract. In some embodiments, the final extract compnses about 4.48% by weight of the CBD extract, about 1.88% by weight of the CBG extract, and about 1.88% by weight of the CBGA extract.

[0110] In another aspect, provided herein is a hemp extract comprising cannabidiolic acid, cannabigerolic acid, and cannabidivarinic acid (termed herein a “CBDA-CBGA-CBDVA” extract). In some embodiments, a CBDA-CBGA-CBDVA extract provided herein comprises 5 mg / mL to 70 mg / mL cannabidiolic acid, 5 mg / mL to 70 mg / mL of cannabigerolic acid, and 5 mg / mL to 70 mg / mL cannabidivarinic acid. In some embodiments, the CBDA-CBGA- CBDVA extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.10111] In some embodiments, the CBDA-CBGA-CBDVA extract comprises cannabidivarinic acid at a concentration of 5 mg / mL to 50 mg / mL. In some embodiments, the extract comprises cannabidivarinic acid at a concentration of 10 mg / mL to 40 mg / mL.

[0112] In some embodiments, the CBDA-CBGA-CBDVA extract comprises cannabigerolic acid at a concentration of 5 mg / mL to 50 mg / mL. In some embodiments, the cannabigerolic acid is present at a concentration of 10 mg / mL to 40 mg / mL.

[0113] In some embodiments, the CBDA-CBGA-CBDVA extract comprises cannabidiolic acid at a concentration of 5 mg / mL to 50 mg / mL. In some embodiments, the cannabidiolic acid is present at a concentration of 10 mg / mL to 40 mg / mL.

[0114] In some embodiments, the CBDA-CBGA-CBDVA extract comprises 5 mg / mL to 50 mg / mL of cannabidiolic acid; 5 mg / mL to 50 mg / mL cannabigerolic acid; and 5 mg / mL to 50 mg / mL of cannabidivarinic acid. In some embodiments, the CBDA-CBGA-CBDVA extract comprises 10 mg / mL to 40 mg / mL of cannabidiolic acid; 10 mg / mL to 40 mg / mL cannabigerolic acid; and 10 mg / mL to 40 mg / mL of cannabidivarinic acid.

[0115] In another aspect, provided herein is a hemp extract comprising cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin (termed herein a “CBDA-CBD-CBGA-CBG-CBDVA-CBDV extract”). In some embodiments, the CBDA-CBD-CBGA-CBG-CBDVA-CBDV extract comprises a specific ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin is 2.4-3.6:0.2- I.2:0.8-I.2:0.8-l .2:0.8-1.2:0.8-1.2. In some embodiments, the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin is 3: 1 : 1 : 1: 1 : 1.

[0116] In some embodiments, a CBDA-CBD-CBGA-CBG-CBDVA-CBDV extract provided herein comprises 5 mg / mL to 30 mg / mL of cannabidiolic acid, 5 mg / mL to 30 mg / mL of cannabidiol, 5 mg / mL to 30 mg / mL of cannabigerolic acid, 5 mg / mL to 30 mg / mL of cannabigerol, 5 mg / mL to 30 mg / mL of cannabidivarinic acid, and 5 mg / mL to 30 mg / mL of cannabidivarin. In some embodiments, the CBDA-CBD-CBGA-CBG-CBDVA-CBDV extract comprises other cannabinoids which are present at reduced concentrations. In some embodiments, other cannabinoids are present at less than 7 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 6 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 5 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 4 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 3 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 2 mg / mL, individually. In some embodiments, other cannabinoids are present at less than 1 mg / mL, individually.

[0117] In some embodiments, a CBDA-CBD-CBGA-CBG-CBDVA-CBDV extract provided herein further comprises at least one of A9-tetrahydrocannabinolic acid and cannabichromene. In some embodiments, a CBDA-CBD-CBGA-CBG-CBDVA-CBDVextract provided herein further comprises A9-tetrahydrocannabinolic acid and cannabichromene.Hemp Extracts - General Characteristics

[0118] Any hemp extracts provided herein can comprise any of the characteristics described below.

[0119] In some embodiments, a hemp extract provided herein comprises about 0.01 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 0.05 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 0.1 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 0.5 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 1 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 2 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 3 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 4 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 5 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 10 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 20 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 30 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 40 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 50 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 60 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 70 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 80 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 90 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 100 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 110 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 120 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises about 130 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises from 50 mg / mL to 130 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises from 60 mg / mL to 120 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises from 70 mg / mL to 120 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises from 50 mg / mL to 80 mg / mL of cannabinoids. In some embodiments, the hemp extract comprises from 80 mg / mL to 120 mg / mL of cannabinoids. In some embodiments, the hempextract comprises from 85 mg / mL to 115 mg / mL of cannabinoids.

[0120] In some embodiments, a hemp extract provided herein comprises from 4% w / w to 20% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 4% w / w to 15% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 6% w / w to 20% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 6% w / w to 15% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 6% w / w to 10% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 8% w / w to 20% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 8% w / w to 15% w / w of total cannabinoids. In some embodiments, the hemp extract comprises from 9% w / w to 13% w / w of total cannabinoids.

[0121] In some embodiments of the hemp extracts provided herein, the concentration of A9- tetrahydrocannabinol is insufficient to produce a psychotropic effect. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is from about 1:50 to about 1: 15. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1:50. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1 :45. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1:40. In some embodiments, the ratio of A9- tetrahydrocannabinol to the other cannabinoids is about 1 :35. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1:30. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1 :25. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1:20. In some embodiments, the ratio of A9-tetrahydrocannabinol to the other cannabinoids is about 1: 15.

[0122] In some embodiments of the hemp extracts provided herein, the concentration of A9- tetrahydrocannabinol is less than about 7 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 6 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 5 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 4 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 3 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 2 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 1.5 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 1 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.9 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.8 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.7 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.6 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.5 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.4 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.3 mg / mL. In some embodiments, the concentration of A9- tetrahydrocannabinol is less than about 0.2 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0. 1 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is less than about 0.05 mg / mL. In some embodiments, the concentration of A9-tetrahydrocannabinol is about 0 mg / mL.

[0123] In some embodiments, a hemp extract provided herein does not comprise terpenes.

[0124] In some embodiments, a hemp extract provided herein comprises 1 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; -ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0125] In some embodiments, a hemp extract provided herein comprises 2 or more of the following terpenes: a-pinene; p-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; [Locimene: eucalyptol; isopulegol; and nerolidol 1.

[0126] In some embodiments, a hemp extract provided herein comprises 3 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0127] In some embodiments, a hemp extract provided herein comprises 4 or more of the following terpenes: a-pinene; P-myrcene; -pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0128] In some embodiments, a hemp extract provided herein comprises 5 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0129] In some embodiments, a hemp extract provided herein comprises 6 or more of thefollowing terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0130] In some embodiments, a hemp extract provided herein comprises 7 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0131] In some embodiments, a hemp extract provided herein comprises 8 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0132] In some embodiments, a hemp extract provided herein comprises 9 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0133] In some embodiments, a hemp extract provided herein comprises 10 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0134] In some embodiments, a hemp extract provided herein comprises 11 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0135] In some embodiments, a hemp extract provided herein comprises 12 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; p-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0136] In some embodiments, a hemp extract provided herein comprises 13 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0137] In some embodiments, a hemp extract provided herein comprises 14 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene;eucalyptol; isopulegol; and nerolidol 1.

[0138] In some embodiments, a hemp extract provided herein comprises 15 or more of the following terpenes: a-pinene; P-myrcene; P-pinene; 6-limonene; linalool; P-caryophyllene; a- humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0139] In some embodiments, a hemp extract provided herein comprises the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a-humulene; nerolidol 2; guaiol; caryophyllene oxide; a-bisabolol; camphene; P-ocimene; eucalyptol; isopulegol; and nerolidol 1.

[0140] In some embodiments, a hemp extract provided herein comprises 1 or more (e.g., 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, or all) of the following terpenes: a-pinene; P-myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a-humulene; nerolidol 2; guaiol; caryophyllene oxide; and a-bisabolol.

[0141] In some embodiments, a hemp extract provided herein comprises about 0.09-0.13% a- pinene; about 0.23-0.44% P-myrcene; about 0.04-0.09% P-pinene; about 0.05-0.09% 8- limonene; about 0.03-0.06% linalool; about 0.04-0.07% P-caryophyllene; about 0.02-0.04% a-humulene; about 0.04-0.07% nerolidol 2; about 0.02-0.04% guaiol; about 0.04-0.08% caryophyllene oxide; and / or about 0.01-0.04% a-bisabolol.

[0142] In some embodiments, a hemp extract provided herein comprises about 0.02% camphene; about 0.02%-0.03% p-ocimene; about 0.02%-0.05% eucalyptol; about 0.02% isopulegol; and / or about 0.02%-0.04% nerolidol 1.

[0143] In some embodiments, a hemp extract provided herein comprises: a-pinene; P- myrcene; P-pinene; 8-limonene; linalool; P-caryophyllene; a-humulene; guaiol; caryophyllene oxide; and a-bisabolol.

[0144] In some embodiments, a hemp extract provided herein comprises: P-myrcene; 8- limonene; p-ocimene; linalool; p-caryophyllene; a-humulene; guaiol; caryophyllene oxide; and a-bisabolol.Pharmaceutical Compositions and Dosage Forms

[0145] In one aspect, provided herein are pharmaceutical compositions comprising any of the hemp extracts described above and a carrier. In some embodiments, the carrier comprises a pharmaceutically acceptable carrier. In some embodiments, the carrier comprises hemp seed oil, linseed oil, olive oil, fish oil, salmon oil, coconut oil, catnip oil, sesame oil, medium chain triglyceride (MCT) oil, lecithin, NF-971P polymer, and / or grapeseed oil. In someembodiments, the carrier comprises hemp seed oil. In some embodiments, the carrier comprises sesame oil.

[0146] In some embodiments, the carrier comprises lecithin. In some embodiments, the lecithin is sunflower lecithin. In some embodiments, the pharmaceutical composition comprises about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or more lecithin (e.g., weight percent).

[0147] In some embodiments, the carrier comprises MCT oil. In some embodiments, the MCT oil is from coconuts (e.g., fractionated coconut oil). In some embodiments, the pharmaceutical composition comprises about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, or more MCT oil (e.g., weight percent). In some embodiments, the pharmaceutical composition comprises from 45% to 55% (e.g., 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or 55%) MCT oil.

[0148] In some embodiments, the pharmaceutical composition comprises more than one carrier. In some embodiments, the pharmaceutical composition comprises lecithin and MCT oil. In some embodiments, the pharmaceutical composition comprises from about 5% to about 70% (e.g., about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70%) lecithin and from about 5% to about 70% (e.g., about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, or about 70%) MCT oil. In some embodiments, the pharmaceutical composition comprises about 40% lecithin and about 50% MCT oil. In some embodiments, the pharmaceutical composition comprises 40% lecithin and from 45% to 55% (e.g., 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, or 55%) MCT oil.

[0149] In some embodiments, the carrier comprises NF-971P polymer. In some embodiments, the NF-971P polymer is about 0.5%, about 1.0%, about 1.5%, about 2.0%, about 2.5%, or about 3.0% weight / volume ratio. In some embodiments, the NF-971P polymer comprises carbomer homopolymer.

[0150] In some embodiments, the pharmaceutical composition is formulated as a sublingual spray. In some embodiments, the pharmaceutical composition is formulated as a water or alcohol soluble solution, a gel, or a cream for topical or transdermal application. In some embodiments, the pharmaceutical composition is applied to the back of the neck. In some embodiments, the pharmaceutical composition is applied via transdermal aural application.In some embodiments, the pharmaceutical composition is formulated as a gel for buccal or mucosal administration. In some embodiments, the pharmaceutical composition is formulated as a paste for buccal or mucosal administration. In some embodiments, the pharmaceutical composition is formulated as a solution for subcutaneous injection. In some embodiments, the pharmaceutical composition is formulated for administration using a nebulizer. In some embodiments, the pharmaceutical composition is formulated for inhalation. In some embodiments, the pharmaceutical composition is formulated as an edible product for oral administration. In some embodiments, the pharmaceutical composition is formulated as a tablet. In some embodiments, the pharmaceutical composition is formulated as a capsule. In some embodiments, the pharmaceutical composition is formulated as a hard chewable. In some embodiments, the pharmaceutical composition is formulated as a soft chewable.

[0151] The pharmaceutical compositions of the present disclosure may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, grinding, pulverizing, dragee-making, levigating, emulsifying, encapsulating, entrapping or by lyophilizing processes.

[0152] The compositions for use in accordance with the present disclosure thus may be formulated in conventional manner using one or more pharmaceutically acceptable earners comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0153] In another aspect, provided herein are dosage forms comprising a hemp extract disclosed herein and at least one of a pharmaceutically acceptable additive (e.g., a carrier as described above), a flavoring agent, a surfactant, and an adjuvant. In some embodiments, the dosage form is formulated as a sublingual spray. In some embodiments, the dosage form is formulated as a water, alcohol, polyethylene glycol, or glycerol soluble solution, a gel, or a cream for topical or transdermal application. In some embodiments, the dosage form is applied to the back of the neck. In some embodiments, the dosage form is applied via transdermal aural application. In some embodiments, the dosage form is formulated as a gel for buccal or mucosal administration. In some embodiments, the dosage form is formulated as a paste for buccal or mucosal administration. In some embodiments, the dosage form is formulated as a gel. In some embodiments, the dosage form is formulated as a powder. In some embodiments, the dosage form is formulated for administration using a nebulizer. In some embodiments, the dosage form is formulated for inhalation. In some embodiments, the dosage form is formulated as a solution for subcutaneous injection. In some embodiments,the composition is formulated as an edible product for oral administration. In some embodiments, the dosage form is formulated as a tablet. In some embodiments, the dosage form is formulated as a capsule. In some embodiments, the dosage form is formulated as a hard chewable. In some embodiments, the dosage form is formulated as a soft chewable. In some embodiments, the dosage form is formulated as a chew for oral administration. In some embodiments, the chew is produced using cold extrusion.

[0154] In some embodiments, a dosage form provided herein is administered at a dose of 4 mg / kg. In some embodiments, the dosage form is administered twice daily for four weeks.

[0155] In some embodiments, a dosage form or pharmaceutical composition provided herein comprises an edible product infused with a hemp extract provided herein. In some embodiments, the edible product is an extruded food product, baked food product, nut butter, spread, pelleted feed, or processed food. In some embodiments, the edible product is a pet food. In some embodiments, the edible product is in a dry, shelf-stable form such as dried fish, dried dairy products, fish meal, fish flour, cereals, flours, carbohy drates, dried fruits, etc. In some embodiments, the edible product is moist or semi-moist. In some embodiments, the edible product contains additives or supplements such as vitamins, minerals, medicinals, etc., for example chemicals, enzymes, etc., capable of removing plaque or tartar from the animal's teeth, etc. In some embodiments, the hemp extract is administered with catnip oil. In some embodiments, any of the dosage forms described can also include catnip.

[0156] In some embodiments, a pharmaceutical composition or dosage form provided herein is administered using a nebulizer. In some embodiments, the nebulizer delivery device and system is capable of effectively and efficiently administering one or more nebulized drugs to a subject. In some embodiments, the nebulizer system can easily be used on subjects (e.g., animals) without removing them from their natural environment. In some embodiments, the nebulizer delivery device and system enables subjects (e g., animals) to be easily treated daily or multiple times a day without undue stress or the need for extensive resources. In some embodiments, the nebulizer delivery device and system can be used on subjects (e.g., animals) having varying levels of training.

[0157] In some embodiments, a pharmaceutical composition or dosage form provided herein is administered using a diffuser. The diffuser can be any device which disperses the pharmaceutical composition or dosage form into the air. The pharmaceutical composition or dosage form may be dispersed by any method, including by natural convection, by forced convection, by heating a wick or pad, for example, holding the pharmaceutical composition or dosage form, by using pumps, or with fans.Methods of Treatment

[0158] In one aspect, provided herein is a method for treating a disease, disorder, syndrome, and / or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of any of the hemp extracts, pharmaceutical compositions, or dosage forms described above.

[0159] In some embodiments, the disease, disorder, syndrome, and / or condition is a neurological disorder. Neurological disorders include, but are not limited to, epilepsy and syndromes associated therewith, Dravet Syndrome, Lennox Gastaut Syndrome, Doose Syndrome, Aicardi Syndrome, CDKL5-related disorders, Dupl5q-related disorders, myocolonic seizures, juvenile mycolonic epilepsy, refractory epilepsy, schizophrenia, juvenile spasms, West syndrome, infantile spasms, refractory infantile spasms, tuberous sclerosis complex, brain tumors, brain injury, traumatic brain injury, neuropathic pain, cannabis use disorder, post-traumatic stress disorder, anxiety, early psychosis, neurodegenerative disorders like Alzheimer's Disease, and autism.

[0160] In some embodiments, the disease, disorder, syndrome, and / or condition is autism spectrum disorder (ASD) and / or an ASD-associated disorder, such as Tuberous Sclerosis Complex, Fragile X syndrome, Cornelia de Lange syndrome, Down syndrome, Angelman syndrome, Coffin-Lowry syndrome, Cohen Laurence-Moon-Biedel syndrome, Marinesco- Sjogren syndrome, Moebius syndrome, Phelan-McDermid syndrome, CDKLS, Dupl5q, Potocki-Lupski syndrome, Smith Lemli Optiz syndrome, Timothy syndrome, Prader-Willi syndrome, Rett syndrome and Williams syndrome.

[0161] In some embodiments, the disease, disorder, syndrome, and / or condition is a neurodegenerative disease or disorder. Neurodegenerative diseases and disorders include Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; Huntington's disease; frontotemporal dementia; prion disease; Lewy body dementia; progressive supranuclear palsy; vascular dementia; normal pressure hydrocephalus; traumatic spinal cord injury; HIV dementia; alcohol induced neurotoxicity; Friedreich’s ataxia; multiple sclerosis; motor neurone diseases; spinal muscular atrophy; Down's syndrome; epilepsy or any other related neurological or psychiatric neurodegenerative disease.

[0162] In some embodiments, the disease, disorder, syndrome, and / or condition is a condition associated with brain injury or damage. In some embodiments, the brain injury or damage is a traumatic brain injury (e.g., diffuse axonal injury, concussion, contusion, whiplash, etc.), an acquired brain injury (e.g., stroke, anoxic brain injury, hypoxic brain injury, etc.), a closed head injury, an open head injury, or any other head injury.

[0163] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.1-100.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1-100.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5-80.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5-80 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.5-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5-50 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10-50.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 15-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 30-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 15-50.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 30-50.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 20-35 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 25-35 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 35-50.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 35-60.0 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0. 1-15.0 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0. 1-10.0 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1- 10.0 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5-10.0 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.5-10.0 mg / kg. In another embodiment, the hemp extract, pharmaceuticalcomposition, or dosage form is administered at a dosage of about 7.5-20.0 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10-30 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 30-100 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is given orally. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is given topically.

[0164] In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0. 1 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.2 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.3 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.4 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.5 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.6 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.7 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.8 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 0.9 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1.5 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 3 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 6 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.5 mg / kg.In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 8 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 9 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 11 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 12 mg / kg. In yet another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 13 mg / kg. In still another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 14 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 15 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 20 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 25 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 30 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 35 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 40 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 45 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 50 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 60 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 70 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 80 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 90 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 100 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 110 mg / kg. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is given orally. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is given topically.

[0165] In some embodiments, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage selected from the group consisting of 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 20 mg / kg, 50 mg / kg, and 60 mg / kg.

[0166] In some embodiments, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of 5 mg / kg to 60 mg / kg.

[0167] In some embodiments, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of 10 mg / kg to 100 mg / kg.

[0168] In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at twice the therapeutically effective dosage for one week, and then subsequently administered at a therapeutically effective dosage. In yet another embodiment, the therapeutically effective dosage is about 0. 1-0.5 mg / kg. In still another embodiment, the therapeutically effective dosage is about 2 mg / kg. In an embodiment, the therapeutically effective dosage is about 8 mg / kg.

[0169] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1 mg / kg for one week, and then subsequently administered at a dosage of about 0. 1-0.5 mg / kg. In another embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4 mg / kg for one week, and then subsequently administered at a dosage of about 2 mg / kg.

[0170] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 1.0 mg / kg four times daily.

[0171] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2.0 mg / kg four times daily.

[0172] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 3.0 mg / kg once daily. In an embodiment, the hemp extract,pharmaceutical composition, or dosage form is administered at a dosage of about 3.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 3.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 3.0 mg / kg four times daily.

[0173] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 4.0 mg / kg four times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 5.0 mg / kg four times daily.

[0174] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 6.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 6.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 6.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 6.0 mg / kg four times daily.

[0175] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 7.0 mg / kg four times daily.

[0176] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 8.0 mg / kg once daily. In an embodiment, the hemp extract,pharmaceutical composition, or dosage form is administered at a dosage of about 8.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 8.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 8.0 mg / kg four times daily.

[0177] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 9.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 9.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 9.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 9.0 mg / kg four times daily.

[0178] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10.0 mg / kg once daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10.0 mg / kg twice daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10.0 mg / kg three times daily. In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 10.0 mg / kg four times daily.

[0179] In an embodiment, the hemp extract, pharmaceutical composition, or dosage form is administered at a dosage of about 2 mg / kg twice daily.

[0180] In an embodiment, a dropperful of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 0.5 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 1 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 2 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 3 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 4 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 5 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 6 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 7 mL of the hemp extract, pharmaceutical composition, or dosage form isadministered to the subject. In another embodiment, 8 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 9 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject. In another embodiment, 10 mL of the hemp extract, pharmaceutical composition, or dosage form is administered to the subject.

[0181] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabidiol (CBD). In another embodiment, the median maximal serum concentration of CBD is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBD is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBD is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBD is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBD is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBD is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBD is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBD is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBD is about 600 ng / mL.

[0182] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabidiolic acid (CBDA). In another embodiment, the median maximal serum concentration of CBDA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBDA is about 100 ng / mL. In still another embodiment, the median maximal serumconcentration of CBDA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBDA is about 200 ng / mL, In another embodiment, the median maximal serum concentration of CBDA is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBDA is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBDA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBDA is about 600 ng / mL.

[0183] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of CBD and CBDA. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBD and CBDA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBD and CBDA is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBD and CBDA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBD and CBDA is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBD and CBDA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBD and CBDA is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBD and CBDA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBD and CBDA is about 600 ng / mL.

[0184] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabigerol (CBG). In another embodiment, the median maximal serum concentration of CBG is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 90 ng / mL. In another embodiment, themedian maximal serum concentration of CBG is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBG is about 90 ng / mL, In still another embodiment, the median maximal serum concentration of CBG is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBG is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBG is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBG is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBG is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBG is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBG is about 600 ng / mL.

[0185] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabigerolic acid (CBGA). In another embodiment, the median maximal serum concentration of CBGA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBGA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBGA is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBGA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBGA is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 300 ng / mL, In yet another embodiment, the median maximal serum concentration of CBGA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBGA is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBGA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBGA is about 600 ng / mL.

[0186] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of CBG and CBGA. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 50ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 70 ng / mL, In another embodiment, the median maximal serum concentration of CBG and CBGA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBG and CBGA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBG and CBGA is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBG and CBGA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBG and CBGA is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBG and CBGA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBG and CBGA is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBG and CBGA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBG and CBGA is about 600 ng / mL.

[0187] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabidivarin (CBDV). In another embodiment, the median maximal serum concentration of CBDV is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDV is about 90 ng / mL, In still another embodiment, the median maximal serum concentration of CBDV is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBDV is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBDV is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDV is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBDV is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBDV is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBDV is about 600 ng / mL.

[0188] In an embodiment, the method results in a therapeutically effective median maximalserum concentration of cannabidivarinic acid (CBDVA). In another embodiment, the median maximal serum concentration of CBDVA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDVA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBDVA is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBDVA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBDVA is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDVA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBDVA is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBDVA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBDVA is about 600 ng / mL.

[0189] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of CBDV and CBDVA. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBDV and CBDVA is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBDV andCBDVA is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 500 ng / mL, In an embodiment, the median maximal serum concentration of CBDV and CBDVA is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBDV and CBDVA is about 600 ng / mL.

[0190] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabinol (CBN). In another embodiment, the median maximal serum concentration of CBN is about 30-90 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 30 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 50 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 70 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 90 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of CBN is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of CBN is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of CBN is about 102 ng / mL. In an embodiment, the median maximal serum concentration of CBN is about 200 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of CBN is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of CBN is about 500 ng / mL. In an embodiment, the median maximal serum concentration of CBN is about 590 ng / mL. In another embodiment, the median maximal serum concentration of CBN is about 600 ng / mL.

[0191] In some embodiments, the subject is human. In some embodiments, the subject is a veterinary subject. In an embodiment, the veterinary subject is canine, feline, bovine, porcine, or equine.

[0192] In an embodiment, the hemp extract is administered at a dosage of about 0. 1-15.0 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 0.1- 10.0 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 0. 1 mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 0.2 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 0.3 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 0.4 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 0.5 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 0.6mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 0.7 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 0.8 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 0.9 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 1 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 1.5 mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 2 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 3 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 4 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 5 mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 6 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 7 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 8 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 9 mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 10 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 11 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 12 mg / kg. In yet another embodiment, the hemp extract is administered at a dosage of about 13 mg / kg. In still another embodiment, the hemp extract is administered at a dosage of about 14 mg / kg. In an embodiment, the hemp extract is administered at a dosage of about 15 mg / kg.

[0193] In another embodiment, the hemp extract is administered at twice the therapeutically effective dosage for one week, and then subsequently administered at a therapeutically effective dosage. In yet another embodiment, the therapeutically effective dosage is about 0. 1-0.5 mg / kg. In still another embodiment, the therapeutically effective dosage is about 2 mg / kg. In an embodiment, the therapeutically effective dosage is about 8 mg / kg.

[0194] In an embodiment, the hemp extract is administered at a dosage of about 1 mg / kg for one week, and then subsequently administered at a dosage of about 0. 1-0.5 mg / kg. In another embodiment, the hemp extract is administered at a dosage of about 4 mg / kg for one week, and then subsequently administered at a dosage of about 2 mg / kg.

[0195] In an embodiment, the method results in a therapeutically effective median maximal serum concentration of cannabidiol. In another embodiment, the median maximal serum concentration of cannabidiol is about 90-310 ng / mL. In yet another embodiment, the median maximal serum concentration of cannabidiol is about 90 ng / mL. In still another embodiment, the median maximal serum concentration of cannabidiol is about 100 ng / mL. In still another embodiment, the median maximal serum concentration of cannabidiol is about 102 ng / mL. Inan embodiment, the median maximal serum concentration of cannabidiol is about 200 ng / mL, In another embodiment, the median maximal serum concentration of cannabidiol is about 300 ng / mL. In yet another embodiment, the median maximal serum concentration of cannabidiol is about 400 ng / mL. In still another embodiment, the median maximal serum concentration of cannabidiol is about 500 ng / mL. In an embodiment, the median maximal serum concentration of cannabidiol is about 590 ng / mL. In another embodiment, the median maximal serum concentration of cannabidiol is about 600 ng / mL.

[0196] The pharmaceutical compositions and dosage forms of the present disclosure may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with any other therapeutic agent. Administration can be systemic or local. In an embodiment, administration is topical.

[0197] The therapeutic compositions of the invention (e.g., hemp extracts) will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semisolid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.

[0198] The composition and dose may vary depending upon the age, weight, and gender of a subject to be administered, target disease, disorder, syndrome, condition, route of administration, and the like. Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, receptor mediated endocytosis (see, e.g., Wu et al. (1987) J. Biol. Chem. 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, topical, transdermal, buccal, sublingual, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically activeagents. Administration can be systemic or local.

[0199] Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose, and / or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0200] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.

[0201] The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, local injection, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the hemp extract, pharmaceutical composition, or dosage form in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared can be filled in an appropriate ampoule.

[0202] Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active components may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethyleneglycols.

[0203] Alternatively, the composition may be in a powder form for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water. The exact formulation, route of administration and dosage may be chosen by the physician familiar with the patient's condition. (See for example Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Chapter I, p. 1). Depending on the severity and responsiveness of the condition treated, dosing can also be a single administration of a slow release composition, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0204] Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, chews, etc. In certain embodiments, for the dosages provided above, they are administered in one serving of an edible product, e.g. 1 mg / kg of hemp extract provided in an individual product.

[0205] Hemp extract, dosage forms, and pharmaceutical compositions described herein can be packaged to provide one or more doses of hemp extract per package. Any suitable type of packaging can be used, including wrappers, pouches, boxes, tubs, cans, blister packs, and bags. Such packaging is convenient and accessible to consumers, enhances the consumer's ease of use, reduces the presence of pathogens, increases shelflife, and reduces spoilage. In an embodiment, the hemp extract, dosage form, or pharmaceutical composition is packaged to provide one or more doses of hemp extract per package. In an embodiment, the package is resealable. In some embodiments, the dosage form is edible. In some embodiments, the edible dosage form is formed into a flat shape that can be more easily divided. In some embodiments, this flat shape is a disk or cookie shape. In some embodiments, the edible dosage form includes indentations to show where the edible dosage form should be divided to provide specific dosages. In some embodiments, the edible dosage form comes in multiple pieces. In some embodiments, each of the multiple pieces provides a certain dosage. In some embodiments, a package contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more pieces. In some embodiments, the package is resealable. In an embodiment, one dose of hemp extract is a therapeutically effective amount. In accordance with the methods disclosed herein, pharmaceutical formulations can be administered to the patient or subject using any acceptable device or mechanism. For example, the administration can be accomplished using a syringe and needle or with areusable pen and / or autoinjector delivery device. The methods of the present invention include the use of numerous reusable pen and / or autoinjector delivery devices to administer a pharmaceutical formulation.

[0206] In an embodiment for non-human animal administration, the term “pharmaceutical” as used herein may be replaced by “veterinary.”

[0207] One skilled in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety.

Claims

CLAIMS1. A pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises cannabidiol; and cannabidiolic acid and wherein the ratio of cannabidiol to cannabidiolic acid is less than 1: 100.

2. The pharmaceutical composition of claim 1, wherein the ratio of cannabidiol to cannabidiolic acid is less than 1: 1000.

3. A pharmaceutical composition comprising hemp extract and a carrier, wherein the hemp extract comprises a raw hemp extract and a decarboxylated hemp extract, wherein the ratio of decarboxylated hemp extract to raw hemp extract is less than 1 : 100.

4. The pharmaceutical composition of claim 3, wherein the ratio of decarboxylated hemp extract to raw hemp extract is less than 1:1000.

5. A pharmaceutical composition comprising cannabidiolic acid, cannabigerolic acid, and cannabigerol, wherein the cannabidiolic acid, cannabigerolic acid, and cannabigerol are present in a ratio of 1.6-2.4:0.8-1.2:0.8-1.2.

6. The pharmaceutical composition of claim 5, wherein the ratio of cannabidiolic acid, cannabigerolic acid, and cannabigerol is about 2:1 :1.

7. A pharmaceutical composition comprising cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin, wherein the ratio of cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin is 2.4-3.6:0.8-1.2:0.8-1.2: 0.8-1.2.

8. The pharmaceutical composition of claim 7, wherein the ratio of cannabidiolic acid, cannabidiol, cannabidivarinic acid, and cannabidivarin is about 3 : 1 : 1 : 1.

9. A pharmaceutical composition comprising cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin, wherein the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin is 2.4-3.6:0.2-1.2:0.8-1.2:0.8-l .2:0.8-1.2:0.8-1.2.

10. The pharmaceutical composition of claim 9, wherein the ratio of cannabidiolic acid, cannabidiol, cannabigerolic acid, cannabigerol, cannabidivarinic acid, and cannabidivarin is about 3:1 :1 : 1 : 1 : 1.

11. The pharmaceutical composition of any one of claims 1-10, wherein the hemp extract further comprises: cannabigerolic acid;A9-tetrahydrocannabinolic acid; and cannabichromene.

12. The pharmaceutical composition of any one of claims 1-11, wherein the hemp extract further comprises four or more of the following: a-pinene;P-myrcene;P-pinene;6-limonene; linalool;P-caryophyllene; a-humulene; nerolidol 2; guaiol; caryophyllene oxide; and a-bisabolol.

13. The pharmaceutical composition of any one of claims 1-12, wherein the concentration of A9-tetrahydrocannabinol is insufficient to produce a psychotropic effect.

14. The pharmaceutical composition of claim 13, wherein the ratio of A9- tetrahydrocannabinol to the other cannabinoids is about 1 :25.

15. The pharmaceutical composition of any one of claims 1-14, wherein the concentration of A9-tetrahydrocannabinol is less than about 5.0 mg / mL.

16. The pharmaceutical composition of claim 15, wherein the concentration of A9- tetrahydrocannabinol is less than about 3.5 mg / mL,17. The pharmaceutical composition of claim 15, wherein the concentration of A9- tetrahydrocannabinol is less than about 3.0 mg / mL.

18. The pharmaceutical composition of claim 15, wherein the concentration of A9- tetrahydrocannabinol is less than about 2.0 mg / mL.

19. The pharmaceutical composition of claim 15, wherein the concentration of A9- tetrahydrocannabinol is less than about 1.0 mg / mL.

20. The pharmaceutical composition of claim 15, wherein the concentration of A9- tetrahydrocannabinol is about 0 mg / mL.

21. The pharmaceutical composition of any of one claims 1-20, wherein the hemp extract comprises: about 0.09-0.13% a-pinene; about 0.23-0.44% P-myrcene; about 0.04-0.09% -pinene; about 0.05-0.09% 5-limonene; about 0.03-0.06% linalool; about 0.04-0.07% -caryophyllene; about 0.02-0.04% a-humulene; about 0.04-0.07% nerolidol 2; about 0.02-0.04% guaiol; about 0.04-0.08% caryophyllene oxide; and about 0.01-0.04% a-bisabolol.

22. The pharmaceutical composition of claim 21, wherein the hemp extract further comprises: camphene; -ocimene; eucalyptol; isopulegol; and / ornerolidol 1.

23. The pharmaceutical composition of claim 22, wherein the hemp extract comprises: about 0.02% camphene; about 0.02-0.03% (3-ocimene; about 0.02-0.05% eucalyptol; about 0.02% isopulegol; and / or about 0.02-0.04% nerolidol 1.

24. The pharmaceutical composition of claim any one of claims 1-23, wherein the hemp extract comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more of the following: a-pinene, 0- myrcene, 0-pinene, 8-limonene, linalool, 0-caryophyllene, a-humulene, nerolidol 2, guaiol, caryophyllene oxide, a-bisabolol, camphene, 0-ocimene, eucalyptol, isopulegol, and nerolidol 1.

25. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of any one of claims 1-24.

26. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising20 mg / mL to 70 mg / mL of cannabidiol and20 mg / mL to 70 mg / mL cannabidiolic acid; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

27. The method of claim 26, wherein the hemp extract comprises20 mg / mL to 40 mg / mL of cannabidiol and20 mg / mL to 40 mg / mL of cannabidiolic acid.

28. The method of claim 26, wherein the hemp extract comprises25 mg / mL to 35 mg / mL of cannabidiol and25 mg / mL to 35 mg / mL of cannabidiolic acid.

29. The method of claim 26, wherein the hemp extract comprises30 mg / mL to 40 mg / mL of cannabidiol and30 mg / mL to 40 mg / mL of cannabidiolic acid.

30. The method of claim 26, wherein the hemp extract comprises30 mg / mL to 60 mg / mL of cannabidiol and30 mg / mL to 60 mg / mL of cannabidiolic acid.

31. The method of claim 26, wherein the hemp extract comprises40 mg / mL to 50 mg / mL of cannabidiol and40 mg / mL to 50 mg / mL of cannabidiolic acid.

32. The method of any one of claims 26-31, wherein the ratio of cannabidiol to cannabidiolic acid in the hemp extract is about 0.6:1 to about 1:0.6.

33. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising20 mg / mL to 70 mg / mL of cannabigerol and25 mg / mL to 70 mg / mL cannabigerolic acid; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

34. The method of claim 33, wherein the hemp extract comprises25 mg / mL to 35 mg / mL of cannabigerol and30 mg / mL to 40 mg / mL of cannabigerolic acid.

35. The method of claim 33, wherein the hemp extract comprises28 mg / mL to 32 mg / mL of cannabigerol and32 mg / mL to 37 mg / mL of cannabigerolic acid.

36. The method of claim 33, wherein the hemp extract comprises30 mg / mL to 40 mg / mL of cannabigerol and30 mg / mL to 40 mg / mL of cannabigerolic acid.

37. The method of claim 33, wherein the hemp extract comprises30 mg / mL to 60 mg / mL of cannabigerol and30 mg / mL to 60 mg / mL of cannabigerolic acid.

38. The method of claim 33, wherein the hemp extract comprises40 mg / mL to 55 mg / mL of cannabigerol and40 mg / mL to 55 mg / mL of cannabigerolic acid.

39. The hemp extract of any one of claims 33-38, wherein the ratio of cannabigerol to cannabigerolic acid in the hemp extract is about 0.6: 1 to about 1 :0.6.

40. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising20 mg / mL to 70 mg / mL of cannabidiolic acid;20 mg / mL to 70 mg / mL cannabigerolic acid; and1 mg / mL to 10 mg / mL of cannabigerol; wherein any other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

41. The method of claim 40, wherein the hemp extract comprises25 mg / mL to 40 mg / mL of cannabidiolic acid;25 mg / mL to 40 mg / mL cannabigerolic acid; and2 mg / mL to 8 mg / mL of cannabigerol.

42. The method of claim 40, wherein the hemp extract comprises30 mg / mL to 34 mg / mL of cannabidiolic acid;30 mg / mL to 34 mg / mL of cannabigerolic acid; and2 mg / mL to 7 mg / mL of cannabigerol.

43. The method of claim 40, wherein the hemp extract comprises30 mg / mL to 40 mg / mL of cannabidiolic acid;30 mg / mL to 40 mg / mL cannabigerolic acid; and1 mg / mL to 10 mg / mL of cannabigerol.

44. The method of claim 40, wherein the hemp extract comprises30 mg / mL to 60 mg / mL of cannabidiolic acid;30 mg / mL to 60 mg / mL cannabigerolic acid; and2 mg / mL to 8 mg / mL of cannabigerol.

45. The method of claim 40, wherein the hemp extract comprises40 mg / mL to 55 mg / mL of cannabidiolic acid;40 mg / mL to 55 mg / mL cannabigerolic acid; and2 mg / mL to 8 mg / mL of cannabigerol.

46. The method of any one of claims 40-45, wherein the ratio of cannabidiolic acid to cannabigerolic acid in the hemp extract is about 0.6: 1 to about 1 :0.6.

47. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising10 mg / mL to 50 mg / mL of cannabidiol;5 mg / mL to 35 mg / mL cannabidiolic acid;5 mg / mL to 35 mg / mL of cannabidivarin;3 mg / mL to 25 mg / mL cannabidivarinic acid; and3 mg / mL to 20 mg / mL of cannabigerolic acid; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

48. The method of claim 47, wherein the hemp extract comprises15 mg / mL to 25 mg / mL of cannabidiol;10 mg / mL to 20 mg / mL cannabidiolic acid;10 mg / mL to 20 mg / mL of cannabidivarin;5 mg / mL to 15 mg / mL cannabidivarinic acid; and5 mg / mL to 10 mg / mL of cannabigerolic acid.

49. The method of claim 47, wherein the hemp extract comprises18 mg / mL to 22 mg / mL of cannabidiol;13 mg / mL to 17 mg / mL cannabidiolic acid;13 mg / mL to 17 mg / mL of cannabidivarin;8 mg / mL to 13 mg / mL cannabidivarinic acid; and5 mg / mL to 10 mg / mL of cannabigerolic acid.

50. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising20 mg / mL to 40 mg / mL of cannabidiol;10 mg / mL to 30 mg / mL cannabidiolic acid;15 mg / mL to 30 mg / mL of cannabidivarin;10 mg / mL to 20 mg / mL cannabidivarinic acid; and8 mg / mL to 20 mg / mL of cannabigerolic acid; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

51. A method of treating a neurological disorder in a subj ect in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising5 mg / mL to 30 mg / mL of cannabidiol;5 mg / mL to 30 mg / mL cannabidiolic acid;5 mg / mL to 30 mg / mL of cannabidivarin; and5 mg / mL to 30 mg / mL cannabidivarinic acid, thereby treating the neurological disorder in the subject.

52. The method of claim 51, wherein the hemp extract comprises10 mg / mL to 25 mg / mL of cannabidiol;10 mg / mL to 25 mg / mL cannabidiolic acid;10 mg / mL to 25 mg / mL of cannabidivarin; and10 mg / mL to 25 mg / mL cannabidivarinic acid.

53. The method of claim 51, wherein the hemp extract comprises12 mg / mL to 22 mg / mL of cannabidiol;12 mg / mL to 22 mg / mL cannabidiolic acid;12 mg / mL to 22 mg / mL of cannabidivarin; and12 mg / mL to 22 mg / mL cannabidivarinic acid.

54. The method of any one of claims 51-53, wherein other cannabinoids are present in the hemp extract at less than 5 mg / mL, individually.

55. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising20 mg / mL to 60 mg / mL of cannabidiol;20 mg / mL to 60 mg / mL of cannabidiolic acid; and5 mg / mL to 30 mg / mL of cannabinol; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

56. The method of claim 55, wherein the hemp extract comprises20 mg / mL to 40 mg / mL of cannabidiol;20 mg / mL to 40 mg / mL of cannabidiolic acid; and5 mg / mL to 20 mg / mL of cannabinol.

57. The method of claim 55, wherein the hemp extract comprises25 mg / mL to 35 mg / mL of cannabidiol;25 mg / mL to 35 mg / mL of cannabidiolic acid; and8 mg / mL to 12 mg / mL of cannabinol.

58. The method of claim 55, wherein the hemp extract comprises30 mg / mL to 55 mg / mL of cannabidiol;30 mg / mL to 55 mg / mL of cannabidiolic acid; and10 mg / mL to 20 mg / mL of cannabinol.

59. The method of claim 55, wherein the hemp extract comprises30 mg / mL to 45 mg / mL of cannabidiol;30 mg / mL to 45 mg / mL of cannabidiolic acid; and10 mg / mL to 20 mg / mL of cannabinol.

60. The hemp extract of any one of claims 55-59, wherein the ratio of cannabidiol to cannabidiolic acid in the hemp extract is about 0.6:1 to about 1:0.6.

61. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising:20 mg / mL to 50 mg / mL of cannabidiol;5 mg / mL to 25 mg / mL of cannabigerol; and5 mg / mL to 25 mg / mL of cannabigerolic acid; wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

62. The method of claim 61, wherein the hemp extract comprises25 mg / mL to 45 mg / mL of cannabidiol;10 mg / mL to 20 mg / mL of cannabigerol; and10 mg / mL to 20 mg / mL of cannabigerolic acid.

63. The method of claim 61, wherein the hemp extract comprises30 mg / mL to 45 mg / mL of cannabidiol;13 mg / mL to 20 mg / mL of cannabigerol; and13 mg / mL to 20 mg / mL of cannabigerolic acid.

64. A method of treating a neurological disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hemp extract comprising:5 mg / mL to 70 mg / mL of cannabidiolic acid;5 mg / mL to 70 mg / mL of cannabigerolic acid; and5 mg / mL to 70 mg / mL of cannabidivarinic acid, wherein other cannabinoids are present at less than 5 mg / mL, individually, thereby treating the neurological disorder in the subject.

65. The method of claim 64, wherein the hemp extract comprises5 mg / mL to 50 mg / mL of cannabidiolic acid;5 mg / mL to 50 mg / mL of cannabigerolic acid; and5 mg / mL to 50 mg / mL of cannabidivarinic acid.

66. The method of claim 64, wherein the hemp extract comprises10 mg / mL to 40 mg / mL of cannabidiolic acid;10 mg / mL to 40 mg / mL of cannabigerolic acid; and10 mg / mL to 40 mg / mL of cannabidivarinic acid.

67. The method of any one of claims 26-66, wherein the total concentration of cannabinoids in the hemp extract is from 50 mg / mL to 130 mg / mL.

68. The method of any one of claims 26-67, wherein the hemp extract further comprises: a-pinene;P-myrcene; -pinene;8-limonene; linalool;P-caryophyllene; a-humulene; guaiol; caryophyllene oxide; and a-bisabolol.

69. The method of any one of claims 26-67, wherein the hemp extract further comprises: P-myrcene;8-limonene;P-ocimene; linalool;P-caryophyllene; a-humulene; trans-nerolidol; guaiol; caryophyllene oxide; and a-bisabolol.

70. The method of any one of claims 26-69, wherein the concentration of A9- tetrahydrocannabinol in the hemp extract is insufficient to produce a psychotropic effect.

71. The method of any one of claims 26-70, wherein the concentration of A9- tetrahydrocannabinol in the hemp extract is less than about 5.0 mg / mL.

72. The method of claim 71, wherein the concentration of A9-tetrahydrocannabinol in the hemp extract is less than about 3.5 mg / mL.

73. The method of claim 71, wherein the concentration of A9-tetrahydrocannabinol in the hemp extract is less than about 3.0 mg / mL.

74. The method of claim 71, wherein the concentration of A9-tetrahydrocannabinol in the hemp extract is less than about 2.0 mg / mL.

75. The method of claim 71, wherein the concentration of A9-tetrahydrocannabinol in the hemp extract is less than about 1.0 mg / mL.

76. The method of any one of claims 25-75, wherein the subject is a human.

Citation Information

Patent Citations

  • Hemp extract for treatment of pain in animals

    US20220211790A1

  • Oral care product with cannabinoid compounds

    US20220304911A1

  • Cannabidivarin preparations for use as a medicament

    US20220387350A1

  • Cannabis cigarette with dose markings

    WO2020016660A2

  • Compositions comprising hemp extract and related treatment methods

    WO2023173060A1